Eric Jeng

Prof. Eric Jeng

University of Florida, Gainesville, Florida, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2020 in ASAIO Journal
Verified
Journal Article
Closed access
EJEric Jeng
Eric Jeng
AMAmber H. Miller
Amber H. Miller
JFJeffrey Friedman
Jeffrey Friedman
STStephen A. Tapia-Ruano
Stephen A. Tapia-Ruano
KRKevin Reilly
Kevin Reilly
MAMustafa Ahmed
Mustafa Ahmed
We reviewed our experience of morbidly obese patients with end-stage heart failure that underwent left ventricular assist device (LVAD) implantation. From January 1, 2008 to January 1, 2018, 240 adult LVADs were implanted at our center. We reviewed the cases of patients presenting with end-stage heart failure and morbid obesity (preoperative body mass index [BMI] ≥ 35 kg/m2) who underwent LVAD-alone, and compared that to a group that underwent LVAD and bariatric surgery (laparoscopic sleeve gastrectomy [LSG]) as a means for weight reduction. Demographic characteristics, perioperative details, BMI, and status of transplant candidacy were recorded. Statistical analysis was performed (SPSS version 25) with χ2 analysis, Kaplan–Meier survival analysis, regression analysis, and Student’s t-test. Twenty-nine patients met criteria and underwent LVAD implantation. Fifteen patients underwent LVAD-alone. Fourteen patients underwent LVAD + LSG. Both groups showed good survival outcomes, LVAD-alone (88.9 ± 5.9 months) versus LVAD +LSG (96.1 ± 12.4 months) but were not significantly different. However, we did note that more patients in the LVAD + LSG group were bridged to heart transplantation (p < 0.001). LVAD-alone and/or LVAD + LSG are both technically feasible and effective treatment options for the long-term survival of morbidly obese patients with end-stage heart failure. Combining LVAD + LSG can help bridge patients to heart transplantation.

14 March 2023 in Frontiers in Medicine
Verified
Journal Article
Open access
CVCarlos A. Valdes
Carlos A. Valdes
OSOmar M. Sharaf
Omar M. Sharaf
MBMark S. Bleiweis
Mark S. Bleiweis
JJJeffrey P. Jacobs
Jeffrey P. Jacobs
MMMohammed Mumtaz
Mohammed Mumtaz
GPGiles J Peek
Giles J Peek
Introduction: Optimal anticoagulation therapy is essential for the prevention of thrombotic and hemorrhagic complications in pediatric patients supported with extracorporeal membrane oxygenation (ECMO). Recent data have demonstrated bivalirudin has the potential to surpass and replace heparin as the anticoagulant of choice.Methods: We conducted a systematic review comparing the outcomes of heparin-based versus bivalirudin-based anticoagulation in pediatric patients supported on ECMO to identify the preferred anticoagulant to minimize bleeding events, thrombotic complications, and associated mortality. We referenced the PubMed, Cochrane Library, and Embase databases. These databases were searched from inception through October 2022. Our initial search identified 422 studies. All records were screened by two independent reviewers using the Covidence software for adherence to our inclusion criteria, and seven retrospective cohort studies were identified as appropriate for inclusion.Results: In total, 196 pediatric patients were anticoagulated with heparin and 117 were anticoagulated with bivalirudin while on ECMO. Across the included studies, it was found that for patients treated with bivalirudin, trends were noted toward lower rates of bleeding, transfusion requirements, and thrombosis with no difference in mortality. Overall costs associated with bivalirudin therapy were lower. Time to therapeutic anticoagulation varied between studies though institutions had different anticoagulation targets.Conclusion: Bivalirudin may be a safe, cost-effective alternative to heparin in achieving anticoagulation in pediatric ECMO patients. Prospective multicenter studies and randomized control trials with standard anticoagulation targets are needed to accurately compare outcomes associated with heparin versus bivalirudin in pediatric ECMO patients.

8 January 2016 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
EJEric Jeng
Eric Jeng
JAJuan M. Aranda
Juan M. Aranda
MAMustafa Ahmed
Mustafa Ahmed
CKCharles T. Klodell
Charles T. Klodell
Obesity poses significant challenges in advanced heart failure patients who otherwise meet criteria for listing for heart transplant. We present a patient who underwent bariatric surgery while on LVAD support that subsequently lost weight and was successfully bridged to heart transplantation.

1 August 2017 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
EJEric Jeng
Eric Jeng
NGNikolaus Gravenstein
Nikolaus Gravenstein
CKCharles T. Klodell
Charles T. Klodell

1 November 2021 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
HLHua Liu
Hua Liu
TJT. Everett Jones
T. Everett Jones
EJEric Jeng
Eric Jeng
KPKevin L. Peng
Kevin L. Peng
YPYong G Peng
Yong G Peng

16 May 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
ABAhmet Bilgili
Ahmet Bilgili
IWIverson Williams
Iverson Williams
OSOmar M Sharaf
Omar M Sharaf
FCFabian Jimenez Contreras
Fabian Jimenez Contreras
YSYuriy Stukov
Yuriy Stukov
EJEric Jeng
Eric Jeng